Galsky MD, et al. Clin. Cancer Res. (2014) cited as Ref 632 in DOI: 10.1038/s41392-020-0110-5 (Q9895)
Revision as of 15:47, 21 May 2020 by Admin (talk | contribs) (Created claim: Property:P105: 3581-3588, #quickstatements; #temporary_batch_1590074839150)
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
| Language | Label | Description | Also known as |
|---|---|---|---|
| English |
Galsky MD, et al. Clin. Cancer Res. (2014) cited as Ref 632 in DOI: 10.1038/s41392-020-0110-5
|
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
|
Statements
Galsky MD
0 references
2014
0 references
Clin. Cancer Res.
0 references
20
0 references
A phase I trial of LY2510924 a CXCR4 peptide antagonist in patients with advanced cancer (English)
0 references
3581-3588
0 references
